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condition improved rapidly after chemotherapy was stopped and plasma exchange (nine sessions) as well
as a maintenance therapy with intravenous immunoglobulins was started. She was almost asymptomatic
seven months after onset of symptoms. This case describes a previously unreported association between
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Abstract
We report a case of a 37- year old female patient with metastatic pancreatic neuroendocrine tumor that developed acute 
motor axonal neuropathy after receiving chemotherapy with capecitabine and temozolomide. She had repeatedly progressed 
after several surgical resections of her liver metastases, other hepatic directed procedures, several sessions of peptide receptor 
radionuclide therapy and two systemic treatment lines. When we started a third line therapy with capecitabine (1500 mg 
absolute twice daily, day 1-14) and temozolomide (360 mg absolute in two divided doses on day 1-5) in a 28 days long cycle, 
she unexpectedly developed a progressive weakness of the upper and lower limbs and dysphagia. The diagnosis of acute motor 
axonal neuropathy was confirmed by nerve conduction studies. The patient`s condition improved rapidly after chemotherapy 
was stopped and plasma exchange (nine sessions) as well as a maintenance therapy with intravenous immunoglobulins was 
started. She was almost asymptomatic seven months after onset of symptoms. This case describes a previously unreported 
association between acute motor axonal neuropathy and chemotherapy with capecitabine and temozolomide.
Keywords: Acute motor axonal neuropathy; Capecitabine; 
Pancreatic neuroendocrine Tumor; Temozolomide
Introduction
Pancreatic Neuroendocrine Neoplasms (pNENs) represent a 
rare tumor type arising from the neuroendocrine cell system of the 
pancreas and are subdivided in “functional” and “nonfunctional” 
tumors depending on whether they release peptide hormones 
leading to specific clinical syndromes [1]. pNENs are classified 
into well-differentiated Neuroendocrine Tumors (NETs) (G1 
to G3) and poorly differentiated Neuroendocrine Carcinomas 
(NECs) (always G3), according to morphology and proliferation 
rate [2]. Prognosis is generally poor with reported median overall 
survival rates varying between 12 and 43 months, depending on 
stage and grade [3]. Surgery is the mainstay of treatment in low 
to intermediate grade pNENS with curative intent and may still be 
indicated for palliative debulking to decrease tumor burden or help 
control hormone production [2]. Furthermore, metastasectomy of 
liver lesions is recommended if complete resection or debulking of 
<90% is feasible [4].
Other hepatic directed procedures include ablative 
therapy, Transarterial Embolization (TAE), Transarterial 
Chemoembolization (TACE) and Selective Internal Radiation 
Therapy (SIRT) [5]. Systemic therapy options include somatostatin 
analogs, Peptide Receptor Radionuclide Therapy (PRRT), 
low dose interferon, everolimus, sunitinib, bevacizumab and 
cytotoxic regimens [2]. The alkylating substances streptozotocin 
and temozolomide appear to have the strongest antitumor 
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activity in pancreatic NENs [6]. The Combination of the Oral 
Fluoropyrimidine Cytotoxic Agent Capecitabine and the Oral 
Alkylating Agent Temozolomide (CAPTEM) has been shown to be 
an effective treatment regimen in patients with advanced pNENs, 
resulting in high objective response rates (70%) and considerably 
low toxicity.
The most frequently observed severe toxicities (grade 3-4) 
are blood and lymphatic system disorders, mucositis, diarrhea 
and nausea [6,7]. Acute Motor (Axonal) Neuropathy (AMAN) 
is considered an immune-mediated variant of Guillain-Barré 
Syndrome (GBS) and it is characterized by acute flaccid symmetrical 
paralysis without sensory deficit that can often be complicated by 
respiratory failure. Most AMAN patients have Campylobacter 
jejuni (C. jejuni)-reactive and various anti-ganglioside antibodies, 
suggesting a strong link between microbial pathogens and the 
disease initiation [8]. So far, it has rarely been observed that GBS 
or any of its variants can complicate chemotherapy [9-15]. To the 
best of our knowledge, this is the first report of AMAN in a patient 
receiving chemotherapy with CAPTEM.
Case Report
In this case a 37-year old female was diagnosed with a 
nonfunctional pancreatic NET G2 (Ki 67: 10%, 10 mitoses/ 10 
HPF) with strong expression of Somatostatin Receptors (SSTR2 
A) and extensive liver metastases. She presented initially with 
epigastric pain, nausea and sporadic diarrhea. The Gallium-68-
DOTA-TATE (DOTA-[Tyr3] Octreotat, SST analog) PET/CT 
showed only a weak uptake of DOTATATE in the pancreas and in 
contrast a high uptake in the liver metastases. Therefore, primary 
surgery was performed with pancreatectomy, splenectomy 
and segmentectomy of liver segment V, in order to remove the 
radionuclide-insensitive part of the disease. The patient overcame 
surgery very well, and all symptoms passed off. In a next step, 
we started a PRRT with Lutetium-177-DOTA-TATE. After four 
cycles of Lutetium-177-DOTA-TATE (7400 MBq per cycle) the 
patient showed a good radiological response in the liver MRI and 
the Gallium-68-DOTA-TATE PET/CT restaging 12 weeks later 
revealed partial remission.
We initiated a systemic therapy with the somatostatin 
analog lanreotide in order to reach prolonged disease stabilization. 
Simultaneously, radioablation of the four most critically located 
liver metastases in liver segment III and VIII was performed, 
allowing a hemihepatectomy on a later time-point. Radiological 
staging (MRI abdomen) after four months showed a stable 
disease in the liver. Because of the young age of the patient 
and the very good performance status, we decided to follow an 
aggressive strategy regarding the liver metastases and a left sided 
hemihepatectomy with atypical resection of liver segments VIII, 
VII, V and radio-ablation in liver segment VII was performed. 
The therapy with lanreotide was continued for 15 months under 
regularly serologic (tumor marker, liver enzymes) and radiological 
(MRI abdomen) controls.
Then, the tumor marker chromogranin A was rising 
from former normal levels at 119 µg/l and liver MRI revealed 
progression of the liver metastases. Systemic therapy was 
switched to everolimus (10 mg orally once daily). However, after 
only one month, progressive disease in the liver was diagnosed 
via MRI abdomen and Gallium-68-DOTA-TATE PET/CT. 
Therefore, four more cycles of PRRT with Lutetium-177-DOTA-
TATE (two cycles with 7400 MBq, two cycles with 7200 MBq) 
were conducted, resulting in regression of the liver metastases. 
Lanreotide was reactivated as maintenance therapy. Five months 
later the Gallium-68-DOTA-TATE PET/CT showed progression of 
the liver metastases and suspicion of a new peritoneal metastasis 
in the Douglas cavity. As the liver metastases were still the leading 
problem, we opted for a local therapy in form of a TACE with 
doxorubicin (150 mg) and continuation of lanreotide. Nevertheless, 
only three months later, liver MRI revealed two progressive and 
one stable liver lesion in liver segments V and VI. Thus, the patient 
underwent microwave ablation of the three liver metastases.
At the same time, a liver biopsy was taken in order to go 
for molecular testing. The Oncomine Tumor Mutation Load Assay 
showed no molecular targets suitable for a targeted therapy, maybe 
necessary in the later course of the disease. Actually, Gallium-68- 
DOTA-TATE PET/CT after three months stated progressive disease 
in the liver, the bone and the peritoneum. Therefore, further local 
therapies were no choice and we planned another session of four 
cycles PRRT. Because of the fulminant progression, we initiated a 
bridging systemic therapy with CAPTEM (oral capecitabine, 1500 
mg absolute twice daily, day 1-14 and temozolomide, 360 mg 
absolute in two divided doses on day 1-5 in a 28 days long cycle) 
before the start of another PRRT. Unexpectedly, already two days 
after therapy start, the patient developed a progressive weakness 
of the upper limbs, followed by a weakness of the lower limbs and 
dysphagia on the other day. Chemotherapy was discontinued.
The neurological examination found mostly symmetrical 
greater proximal paresis of the upper limbs and greater distal 
paresis of the lower limbs without impairment of the sensory 
modalities. The muscle-self reflexes were reduced. MRI scan of 
the brain and the cervical and thoracic spine were unremarkable. 
Nerve Conductions Studies (NCS) and needle Electromyography 
(EMG) were performed. NCS included motor conduction studies 
in median, ulnar, tibial and peroneal nerves, along with sensory 
NCS in median and ulnar nerves. They revealed an axonal motor 
polyneuropathy with reduced Compound Muscle Action Potential 
(CMAP) amplitudes especially in the lower limbs and prolonged 
distal motor latencies four days after clinical onset. Motor 
conduction blocks in the ulnar and the median nerve as well as 
in the peroneal nerve on the left side and absent F-waves were 
found eight days later. Repetitive nerve stimulation tests of the 
Citation: Pircher M, Schreiner B, Engel-Bicik I, Far E, Nowak KA, et al. (2020) Acute Motor Axonal Neuropathy in a Patient with Metastatic Pancreatic Neuroendocrine 
Tumor Receiving Chemotherapy with Capecitabine and Temozolomide: A Case Report. Ann Case Report 14: 482. DOI: 10.29011/2574-7754.100482
3 Volume 14; Issue 07
Ann Case Rep, an open access journal
ISSN: 2574-7754
ulnar nerve and sensory nerve conduction studies were normal 
(Figure1).
Cerebrospinal fluid (CSF) analysis performed four days 
after clinical onset showed no pathologies especially the white 
cell count and protein were within normal range. CSF glucose and 
lactate were normal. The routine diagnostic workup at admission 
including serum potassium, Creatine Kinase (CK) and infection 
serology were either normal or negative. Anti-ganglioside 
antibodies, anti-CNS antibodies (including anti-Hu, Ri, Yo, 
amphiphysin, CV2 (CRMP5), Ta/Ma2, Ma1, SOX1, GAD65, 
ZIC4 and Tr) and anti-voltage-gated calcium channel (VGCC) 
antibodies were negative. The clinical and electrodiagnostic 
findings altogether led to the diagnosis of a tetraparetic AMAN. 
A nerve biopsy was not performed because the patient`s condition 
improved considerably within the next weeks. The patient was 
admitted to the neurologic Intensive Care Unit (ICU) and treated 
with nine sessions of plasma exchange.
After the third plasma exchange, she already showed 
increasing muscle strength in the lower limbs. After nine 
sessions she showed remarkable recovery and when she was 
discharged home (after one month), she was able to eat and walk 
independently again. Afterwards, a maintenance therapy with 
intravenous Immunoglobulins (IVIg) was established and is still 
going on after seven months (IVIg 2g/kg over five days per cycle 
per month). Four months after clinical onset (and during the third 
cycle of IVIg), the NCS were repeated and showed a pronounced 
improvement with partially recovered or even normalized CMAP 
amplitudes paralleling the clinical recuperation. The signs of 
conduction blocks had disappeared (Figure 1). Accordingly, the 
IVIg dose per cycle could be reduced without clinical relapse. 
Now, seven months later, the only symptom the patient complains 
of is a slight weakness in both arms.
Figure 1: NCS on day 4, day 12 and after 4 months.
Discussion
Our patient fulfills the clinical and electrodiagnostic 
criteria for the AMAN variant of GBS, appearing shortly 
after initiation of chemotherapy with CAPTEM for metastatic 
pNET [16]. GBS or any of its variants is an acute inflammatory 
polyradiculoneuropathy, characterized by the acute onset of 
peripheral and cranial nerve dysfunction. The typical clinical 
picture is an acute flaccid paralysis, characterized by symmetrical 
ascending weakness of the limbs, and hyporeflexia or areflexia, 
which reaches a maximum severity within four weeks. Myelin or 
the axons of peripheral nerves can be primarily injured, resulting 
in demyelinating or axonal forms of GBS: Acute Inflammatory 
Demyelinating Polyneuropathy (AIDP) or Acute Motor Axonal 
Neuropathy (AMAN), or other variants. In the pure motor form 
AMAN, the axonal polyneuropathy is not accompanied by sensory 
deficits at clinical and electrophysiological examination.
Owing to axonal degeneration, usually the disease progresses 
more rapidly than in AIDP and a prolonged recovery is typical. The 
diagnosis of GBS is a clinical one, but additional investigations can 
be helpful or even needed for confirmation. Examination of CSF 
excludes other causes of weakness, associated with an increase 
in CSF cell count. Typical for GBS is the cytoalbuminologic 
dissociation: the combination of a normal cell count and increased 
protein level. However, normal protein levels (especially when 
determined in the first week after onset of disease) do not make 
the diagnosis unlikely or even exclude GBS [8,17]. Actually, 
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our patient had no cytoalbuminologic dissociation at the initial 
evaluation four days after clinical onset. A lumbar puncture was 
not repeated at a later time point because of the favourable clinical 
course. Furthermore, Nerve Conduction Studies (NCS) can help 
to support the diagnosis of GBS and to differentiate between the 
axonal and the demyelinating subform. Features of AMAN are 
decreased motor amplitudes, but - similar to the case presented 
here - transient conduction blocks and slowing have been described 
in some patients as well.
They are possibly caused by impaired conduction at the 
nodes of Ranvier [18]. GBS is thought to result from an immune 
response to a preceding respiratory or gastrointestinal infection 
or an immunization which cross-reacts with peripheral nerve 
components because of molecular mimicry. C. jejuni is hereby 
the predominantly described infection with 25-50 %. Other 
associated infections are Cytomegalovirus (CMV), Epstein 
Barr Virus (EBV), influenza A virus, Mycoplasma pneumoniae, 
Haemophilus influenzae, hepatitis E, zika- and chikungunya virus. 
Regarding immunization, GBS was observed after vaccination 
with Semple rabies vaccine and various types of influenza A virus 
vaccine [8,17]. Notably our patient did not report any infection 
or immunization within the preceding four weeks. According 
to the obvious temporal association between AMAN and 
chemotherapy initiation, the issue mostly meriting discussion is 
whether AMAN was triggered by CAPTEM chemotherapy or if 
it was just a coincidence. This is particularly of concern, as the 
first neurological symptoms occurred only two days, after the 
CAPTEM chemotherapy was started.
It also points to a mechanism of injury different from the 
classic concept of “molecular mimicry” as the interval seems too 
short for the generation of cross-reactive B and T cell responses. 
GBS as a complication of chemotherapy has rarely been observed. 
There exist few reports of GBS manifestation in cancer patients 
treated with platinum compounds, nab-paclitaxel, vincristine, 
cytarabine or cladribine and only one case of a pure AMAN was 
reported [9-15]. However, in all of these cases it was not possible 
to verify a clear correlation between AMAN and the administration 
of chemotherapy and the underlying mechanisms remain unclear. 
Notably, all these substances are known to induce neurotoxicity in 
form of peripheral polyneuropathy and it was assumed that maybe 
other types and mechanisms of neurotoxicity exist for these drugs, 
which are not common and have not been recognized yet [12]. 
Thus, it was suggested that nab-paclitaxel induced an increase in 
proinflammatory cytokines leading to an immune-mediated insult 
in the axolemma, triggering AMAN. As another explanation, it was 
assumed that taxane-based chemotherapy induced macrophage 
infiltration and injury in the axolemma at the nodes of Ranvier 
[19].
In support of this, pathologically, AMAN is a pure motor 
axonopathy without demyelination as a result of inflammatory 
mononuclear infiltrates and evidence of macrophage-mediated 
phagocytosis on the axolemma [20]. In contrast, neurotoxicity 
is not frequently described in CAPTEM chemotherapy [6,7]. A 
global search of the WHO pharmacovigilance database VigiBase® 
for temozolomide reveals 15.207 Individual Case Safety Reports 
(ICSRs) since 1997, of which 2.780 (18.3%) are categorized 
under the System Organ Class (SOC) “nervous system disorders” 
[21]. 54 (1.9%) ICSRs have been labelled with the primary term 
“neuropathy peripheral”. Only one case documented an axonal 
neuropathy with a reaction onset latency of approximately 
four months. Pharmacovigilance reporting for capecitabine 
encompasses 61.905 ICSRs globally, 7.814 ICSRs (12.6%) under 
SOC: “nervous system disorders” including 161 cases (2.1%) of 
peripheral neuropathies, specifying one case of axonal neuropathy. 
Unfortunately, the case details of capecitabine leading to axonal 
neuropathy do not contain a reaction time onset [21].
Temozolomide is a prodrug of the alkylating agent 
Monomethyl-Triazen-Imidazol-Carboxamid (MTIC). After 
administration, temozolomide is quickly absorbed (Tmax 0.5 - 1.5 
h) in the intestine, roughly 10-20 % are protein bound and activation 
occurs non-enzymatically by hydrolysis. With a mean elimination 
half-life of approximately 1.8 hours, most of the applied substance 
is excreted as metabolites by the kidney. Capecitabine itself is non-
toxic and readily bioavailable when ingested. After initial hepatic 
transformation to 5’-desoxy-5-fluorocytidine and further (preferred 
tumor-specific) activation to the antimetabolite 5-Fluorouracil (5-
FU), it inhibits protein-biosynthesis. Detoxification is initiated by 
the enzyme Dehydropyrimidine-Dehydrogenase (DPD), which 
determines the speed of elimination. A lack of DPD or a, not all 
that unusual, mutation in the DPYD-allele (i.e. DPYD*2A) can 
lead to elevated toxicities, hence pharmacogenetic testing prior to 
exposure is recommended. Notably, our patient was not harbouring 
such a mutation.
In healthy subjects, elimination half-life of capecitabine is 
short with approximately 0.85 h, though the metabolite α-Fluoro-
β-Alanin (FBAL) has an elimination half-life of 3.23 hours. 
Both temozolomide and capecitabine respectively their active 
metabolites, are eliminated quite rapidly, raising doubt whether 
the observed neurotoxicity might be mediated by the substances, 
their metabolites, or rather triggered by an immunogenic response 
[21]. The standardized case causality assessment of WHO-UMC 
(Uppsala Monitoring Centre) describes adverse drug reactions as 
rarely specific to a drug and diagnostic tests are often missing. 
Repeated administration of the substance (re-challenge) is usually 
not ethically justified [22]. To narrow down the possible causes 
a combination of intrinsic (pharmacologic aspects of the case 
history) and extrinsic (documentation in literature and databases) 
parameters serve to verify causality. Beside of CAPTEM 
chemotherapy the tumor itself could potentially trigger AMAN in 
form of a paraneoplastic neurological syndrome. To our knowledge, 
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there has been described only one case of paraneoplastic AMAN 
in anal cancer [23].
Neuroendocrine Neoplasms (NENs) are in fact frequently 
associated with paraneoplastic syndromes, but usually in form of 
metabolic disorders that are attributed to the neoplastic secretion 
of functional peptides, hormones, cytokines and growth factors. 
Neurological paraneoplastic syndromes are not typical for NENs 
and only one case of paraneoplastic Eaton- Lambert myasthenic 
syndrome in an undifferentiated small cell carcinoma of the larynx 
has been reported so far [24]. However, in our case the simultaneous 
beginning of the symptoms with the start of CAPTEM therapy and 
the lack of any neurological symptoms before CAPTEM initiation 
are strong arguments against a paraneoplastic syndrome. IVIg and 
plasma exchange are effective treatment strategies for all types of 
GBS [17]. Our patient improved during plasmapheresis and IVIg 
treatment, which could point to an inflammatory mechanism for 
the development of AMAN here, or be unrelated.
Conclusion
We believe that our patient developed AMAN as a result of 
CAPTEM. It remains unclear which mechanism caused AMAN 
and if only one drug or both drugs contributed to this disease. By 
describing this previously unreported association, we want to raise 
awareness of a possible relationship between them.
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